{"translation_price":"50","translation_doc_price":"40","child_coefficient":"1.1","transfer_price":"2.00","transfer_price_vip":"5.00","constant_transfer_price_vip":350,"constant_transfer_price":150,"constant_transfer_distanse":60,"type":"treatment","program_full_story":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Non-Hodgkin lymphoma (B-cell) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div><div class=\"program_required_documents mt-4\"><h4>Required documents<\/h4><ul>\n\t<li>Complete blood count with white blood cell count<\/li>\n\t<li>Biochemical blood test (renal and liver function tests), if available<\/li>\n\t<li>Bone marrow biopsy results<\/li>\n\t<li>CT scan, if available<\/li>\n<\/ul>\n<\/div>","program_full_story_crm":"<ul>\n\t<li>Initial presentation in the clinic<\/li>\n\t<li>Clinical history taking<\/li>\n\t<li>Physical examination<\/li>\n\t<li>Review of medical records<\/li>\n\t<li>Laboratory tests:\n\t<ul>\n\t\t<li>Complete blood count<\/li>\n\t\t<li>General urine analysis<\/li>\n\t\t<li>Biochemical blood test (kidney and liver function tests)<\/li>\n\t\t<li>Indicators of inflammation (CRP, ESR)<\/li>\n\t\t<li>Indicators of blood coagulation<\/li>\n\t\t<li>Immunohistochemical and genetic analysis of tumor cells (if indicated)<\/li>\n\t<\/ul>\n\t<\/li>\n\t<li>Leukapheresis, processing of T-cells and cultivation of CAR T-cells<\/li>\n\t<li>Adjuvant chemotherapy<\/li>\n\t<li>Infusion of modified CAR T-cells to a patient<\/li>\n\t<li>Control examinations<\/li>\n\t<li>Cost of essential medicines and materials<\/li>\n\t<li>Nursing services<\/li>\n\t<li>Full hospital accommodation<\/li>\n\t<li>Explanation of future recommendations<\/li>\n<\/ul>\n<div class=\"program_indications_for_surgery\"><h4>Indications<\/h4><ul>\n\t<li>Non-Hodgkin lymphoma (B-cell) that is resistant to the conventional therapy<\/li>\n<\/ul>\n<\/div><div class=\"program_how_program_going mt-4\"><h4>How program is carried out<\/h4><p><strong>Days 1-2<\/strong>. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.<\/p>\n\n<p><strong>Day 3<\/strong>. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.<\/p>\n\n<p><strong>Days 4-12<\/strong>. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.<\/p>\n\n<p><strong>Day 13<\/strong>. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.<\/p>\n\n<p><strong>Day 14 and other days<\/strong>. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.<\/p>\n<\/div>","is_ambulant":"0","bh_fee":"0","only_for_children":"0","no_service":"0","with_prepayment":"1","show_calculator":"1","paket_type":"1","btn_type":"0","clinic_icon":"5ffc406182699.jpg","city":"Mannheim","clinic_site":"https:\/\/w2.umm.de\/start\/","department_recommend":"1","country":"Germany","country_id":"1","clinic_name":"University Hospital Mannheim","cinic_name":"University Hospital Mannheim","department_id":"2410","duration":"21","direction":"Hematology","min_duration":0,"clinic_id":"1733","paketPrice":36000,"paket":"<ul>\n <li>Interpreter up to 80 hours<\/li>\n <li>Translation up to 15 pages<\/li>\n <li>Visa support<\/li>\n<\/ul>","title":"Treatment of Non-Hodgkin lymphoma (B-cell) with CAR T-cell therapy","price":{"val":495874.69,"type":"val"},"price_surcharge":0,"price_surcharge_clear":0,"extra_service_clinic":[{"id":"need_to_use_head_doctor","title":"Treatment by leading experts","type":"val","val":null,"req":0},{"id":"1_person_room","title":" Single room (whole period)","parent":"duration","type":"count_val","val":"42.00"},{"id":"attendant_place","title":"Accommodation for the accompanying person ","parent":"duration","type":"count_val","val":"90.00"}],"extra_service":[],"translation_hours":"0","translation_doc_count":null,"roads":[{"id":"6","distance":"69","airport_title":"Frankfurt a.M."},{"id":"19","distance":"128","airport_title":"Stuttgart"},{"id":"27","distance":"237","airport_title":"N\u00fcrnberg"}],"pakets":[],"lang":{"day":"Day","days":"days","ambulatory":"Outpatient","stationaryProgram":"Inpatient"}}
Treatment of Non-Hodgkin lymphoma (B-cell) with CAR T-cell therapy in University Hospital Mannheim
Biochemical blood test (kidney and liver function tests)
Indicators of inflammation (CRP, ESR)
Indicators of blood coagulation
Immunohistochemical and genetic analysis of tumor cells (if indicated)
Leukapheresis, processing of T-cells and cultivation of CAR T-cells
Adjuvant chemotherapy
Infusion of modified CAR T-cells to a patient
Control examinations
Cost of essential medicines and materials
Nursing services
Full hospital accommodation
Explanation of future recommendations
Indications
Non-Hodgkin lymphoma (B-cell) that is resistant to the conventional therapy
How program is carried out
Days 1-2. Initial presentation at the clinic. The doctor collects the patient's medical history, looks at his medical records and previous examinations. Special attention is paid to previous cancer treatments and their results, since CAR T-cell therapy is indicated only if the conventional treatment protocols are ineffective. Based on the results of the consultation, the doctor administers the examination, which includes a complete blood count with white blood cell count, assessment of liver and kidney function, immunohistochemical and genetic analysis of tumor cells (if indicated) and other studies.
Day 3. Collecting patient’s blood. During the leukapheresis procedure, doctors harvest at least 100 million T-cells, which will subsequently undergo gene modification. If there are certain clinical reasons, and the patient needs to postpone the subsequent stages of CAR T-cell therapy, the harvested T-cells undergo the procedure of cryoconservation. If the patient is able to continue treatment immediately, then the harvested T-cells are transferred to the laboratory.
Days 4-12. Processing and gene modification of the T-cells pool lasts 7-10 days. During this time, the patient is receiving immunosuppressive chemotherapy drugs. The chemotherapy is aimed at suppressing the patient's own immune system, which will allow CAR T-cells to fight the tumor more effectively.
Day 13. Manufactured CAR T-cells are tested for the microbiological safety and functional activity. After the successful testing completion, the solution with CAR T-cells is administered to the patient intravenously.
Day 14 and other days. Control examination and further medical supervision in the hospital are carried out. If there are no side effects of CAR T-cell therapy, a stable tendency towards normalization of blood count is observed and the patient has stable general health condition, the patient is discharged from the hospital. Before the discharge, the patient receives the detailed recommendations for further follow-up during the disease remission.
Required documents
Complete blood count with white blood cell count
Biochemical blood test (renal and liver function tests), if available
Bone marrow biopsy results
CT scan, if available
Service
Price from: On request
Type of program :
Price for 1 day: On request
Expected duration of the program:
The minimum duration of the program:
Select
You may also book:
Hospital directly:On request
Saving:On request
BookingHealth Price from:
On request
About the department
The Department of Hematology and Oncology at the University Hospital Mannheim offers the full range of services in these medical fields. It diagnoses and treats all benign and malignant blood diseases, cancers. The huge clinical experience and high competence of the doctors working in the department allow them to achieve excellent treatment results even in the most severe cases. The department is headed by Prof. Dr. med. Georgia Metzgeroth.
The main clinical focuses of the department include:
Complex diagnostics of malignant diseases of all organs and blood
All types of drug therapy for the treatment of malignant diseases
Chemotherapy
Immunotherapy
Hormonal therapy
Other targeted therapies
Treatment of complications after chemotherapy
Other services
The medical team of the department makes every effort to help patients overcome serious diseases and improve the quality of life.
Curriculum vitae
2010 Visiting Professor, Additional Qualification in Palliative Medicine.
Since 2008, Head of the Department of Hematology and Oncology at the University Hospital Mannheim, Heidelberg University.
2007 Habilitation. Subject: "Soluble transferrin receptor in hematology" (Prof. Dr. med. R. Hehlmann, Prof. Dr. med. Hochhaus), focuses: Hematology and Internal Oncology.
2005 Medical Specialist in Internal Medicine.
1999 Admission to Medical Practice.
1997 Doctor’s Degree: "Urodynamic parameters and results of surgery to treat urinary incontinence" (Supervisor: Prof. Dr. Dr. h. c. mult. W. Schmidt).
1997 - 1999 Intern and Assistant Physician, Department of Internal Medicine IV, University Hospital Aachen (Prof. Dr. med. R. Osieka).
1991 - 1997 Study of Medicine, Saarland University, Homburg.
Photo of the doctor: (c) Universitätsklinikum Mannheim
About hospital
According to the reputable Focus magazine, the University Hospital Mannheim ranks among the top medical institutions of Germany, which is an undeniable confirmation of the impeccable medical care and excellent reputation of the hospital!
The hospital is a high-tech modern medical institution, which provides accurate diagnosis and optimal treatment, combined with quality, responsive care, attention to the patient’s individual needs and wishes.
The history of the hospital dates back to 1701. At that time it was a small medical facility, but today it has about 30 specialized departments, centers and institutes with 4,800 first-class medical personnel.
Since the hospital functions on the basis of the Medical Faculty of the Heidelberg University, medical research is constantly conducted here at the national and international levels.
The main clinical focuses of the hospital include surgery, cardiology, oncology and hematology, gastroenterology, neurology, neurosurgery, urology, orthopedics, radiology, pediatric and adolescent medicine.
It should be noted that the hospital was repeatedly awarded prestigious quality certificates, for example, KTQ, IQM certificates, the certificate of the German Cancer Association.
Photo: (c) depositphotos
Accommodation in hospital
Patients rooms
The patients of the University Hospital Mannheim live comfortable single and double patient rooms. All rooms have an attractive design. They are fitted out with modern furniture, TV and a telephone. In addition, each room has an ensuite bathroom with a shower and a toilet. There is a beautiful park near the hospital, where one can walk, enjoying the greenery and clean air.
Meals and Menus
The patients of the hospital are offered delicious, balanced meals: breakfast, lunch with three menus to choose from and buffet dinner. In addition, the menu features dietary dishes. The lobby of the hospital houses a cafe where one can taste cold and hot drinks, have a snack with fresh pastries.
Further details
Standard rooms include:
Shower
Toilet
TV
Wi-Fi
Select your currency:
EUR - €
USD - $
RUB - ₽
KZT - ₸
UAH - ₴
INR - ₹
CNY - ¥
AED - د.إ
SAR - ﷼
Your guarantee
One year of support after the treatment
Insurance to cover unforeseen expenses arising from complications during and 48 months after treatment (coverage up to 200,000 €)
Reduced costs by 40-70% (contracts with Hospitals)
In addition, we are the only TÜV-certified company with an ISO 9001:2015 certificate